An anonymous director reports

ZYUS LIFE SCIENCES ANNOUNCES LIFE OFFERING OF A MINIMUM OF C$15 MILLION AND MAXIMUM OF C$16 MILLION OF UNITS

Zyus Life Sciences Corp. has launched a brokered private placement of a minimum of 23,809,523 units of the company and up to a maximum of 25,396,825 units, at a price of 63 cents per unit, for minimum gross proceeds of $15-million and maximum gross proceeds of up to $16-million.

Each unit will comprise one common share of the company and one-half of one common share purchase warrant. Each warrant will entitle the holder to purchase one additional common share at an exercise price of 85 cents for a period of 24 months from the date of issuance.

The LIFE (listed issuer financing exemption) offering will be conducted on a best efforts, fully marketed basis by Canaccord Genuity Corp., acting as sole lead agent and sole bookrunner, on behalf of a syndicate of agents to be formed.

In connection with the LIFE offering, the company has agreed to pay the agents a cash commission of 5.0 per cent of the gross proceeds of the LIFE offering and to issue agents' warrants equal to 5.0 per cent of the number of units sold under the LIFE offering, with each agent's warrant exercisable for one common share at the offering price for a period of 36 months from the date of issuance. Subscriptions from purchasers on the president's list up to a maximum of $5-million will be subject to reduced compensation of 2.5 per cent in cash and 2.5 per cent in agents' warrants. In addition, the company will pay the lead agent a corporate finance fee, consisting of: (i) a cash fee equal to 2.0 per cent of the gross proceeds of the LIFE offering; and (ii) corporate finance warrants equal to 2.0 per cent of the number of units sold under the LIFE offering, in each case excluding president's list subscriptions.

The net proceeds of the LIFE offering will be used to advance the continuing clinical development of the company's lead drug candidate, Trichomylin softgel capsules, including completion of the company's phase 2a clinical trial and preparation for phase 2b, as well as for working capital and general corporate purposes.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106, Prospectus Exemptions, the units will be offered for sale to purchasers resident in all provinces of Canada other than Quebec pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106, Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 of the Canadian Securities Administrators. The units may also be offered in the United States on a private placement basis pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended, and in such other jurisdictions as may be agreed upon, in each case in accordance with applicable laws. As the LIFE offering is being completed pursuant to the LIFE exemption, the units, together with the underlying common shares and warrants, issued pursuant to the LIFE offering will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document related to the LIFE offering that can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read the offering document before making an investment decision. Copies of the offering document may also be obtained from the lead agent at ECM@cgf.com.

The common shares of the company are listed on the TSX Venture Exchange under the symbol ZYUS. Closing of the LIFE offering is expected to occur on or about Jan. 29, 2026, or such other date as the company and the lead agent may agree, subject to receipt of all necessary regulatory approvals, including approval of the TSX-V.

About Zyus Life Sciences Corp.

Zyus is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.